EGFR and colorectal carcinoma: However, while KRAS amplification is a recurrent event in CRC and designated as likely oncogenic by the OncoKB knowledge base [50], at present, KRAS amplification per se is not a contraindication for anti-EGFR therapy [51] and its clinical significance remains uncertain.